Clinical pharmacology of lumiracoxib, a second-generation cyclooxygenase 2 selective inhibitor

By Bannwarth Bernard   Berenbaum Francis  

Expert Opinion on Investigational Drugs, Vol. 14, Iss. 4, 2005-04 ,pp. : 521-533

Informa Healthcare

Access to resources Recommend Favorite

Clinical Pharmacokinetics and Pharmacodynamics of Celecoxib: A Selective Cyclo-Oxygenase-2 Inhibitor

By Davies N.M.  

Clinical Pharmacokinetics, Vol. 38, Iss. 3, 2000-03 ,pp. : 225-242

Adis International

Access to resources Recommend Favorite

Balancing Gastroprotection and Cardioprotection with Selective Cyclo-Oxygenase-2 Inhibitors: Clinical Implications

By Meagher E.A.  

Drug Safety, Vol. 26, Iss. 13, 2003-01 ,pp. : 913-924

Adis International

Access to resources Recommend Favorite

Pharmacokinetics of Rofecoxib: A Specific Cyclo-Oxygenase-2 Inhibitor

By Davies N.M.  

Clinical Pharmacokinetics, Vol. 42, Iss. 6, 2003-01 ,pp. : 545-556

Adis International

Access to resources Recommend Favorite

Celecoxib, a selective cyclo-oxygenase-2 inhibitor reduces the severity of experimental colitis induced by dinitrobenzene sulfonic acid in rats

By Cuzzocrea S.   Mazzon E.   Serraino I.   Dugo L.   Centorrino T.   Ciccolo A.   Sautebin L.   Caputi A.P.  

European Journal of Pharmacology, Vol. 431, Iss. 1, 2001-11 ,pp. : 91-102

Elsevier

Access to resources Recommend Favorite